Brief: Quoin Pharmaceuticals Announces Positive Interim Data From Two Ongoing Netherton Syndrome Clinical Studies
18/12/2024 13:38
Dec 18 (Reuters) - Quoin Pharmaceuticals Ltd 2EBy.BE :
* QUOIN PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM DATA FROM
TWO
ONGOING NETHERTON SYNDROME CLINICAL STUDIES
* SIGNIFICANT IMPROVEMENT IN SKIN APPEARANCE OBSERVED IN
PEDIATRIC
STUDY AFTER ONLY 12 DAYS OF DOSING WITH QRX003
Source text: ID:nGNX5spTXl
Further company coverage: 2EBy.BE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Quoin Pharmaceuticals
See all newsQuoin Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary
Quoin Pharmaceuticals Ltd expected to post a loss of $1.61 a share - Earnings Preview
Quoin Pharmaceuticals Ltd expected to post a loss of $1.61 a share - Earnings Preview
NASDAQ RESUMED AT 10:15 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:06 AM